<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02576951</url>
  </required_header>
  <id_info>
    <org_study_id>16084</org_study_id>
    <secondary_id>I5Q-MC-CGAO</secondary_id>
    <nct_id>NCT02576951</nct_id>
  </id_info>
  <brief_title>A Study of LY2951742 in Healthy Participants</brief_title>
  <official_title>Tolerability, Pharmacokinetics and Pharmacodynamics of LY2951742 in Healthy Subjects Following a Subcutaneous Administration of a Lyophilized Formulation or a Solution Formulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are:

        -  To evaluate tolerability of the LY2951742 solution injectable formulation (Part A)

        -  To measure how much of the LY2951742 lyophilized (freeze dried) injectable formulation
           is absorbed into the blood stream and how long it takes the body to get rid of it
           compared to the LY2951742 solution injectable formulation after a single injection under
           the skin (subcutaneous [SC]) (Part B).

      Information about any side effects that may occur will also be collected. Each part of the
      study will last about six months. Participants may only enroll in one part.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 19, 2015</start_date>
  <completion_date type="Actual">January 8, 2018</completion_date>
  <primary_completion_date type="Actual">September 3, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants with an Injection Site Adverse Event</measure>
    <time_frame>Part A: Predose through 48 hours after study drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Relative Bioavailability of Lyophilized to Solution Formulations on the Basis of Area Under the Concentration Versus Time Curve (AUC) of LY2951742</measure>
    <time_frame>Part B: Predose through 5 months after study drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Relative Bioavailability of Lyophilized to Solution Formulations on the Basis of Maximum Concentration (Cmax) of LY2951742</measure>
    <time_frame>Part B: Predose through 5 months after study drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of Plasma Calcitonin Gene Related Peptide (CGRP)</measure>
    <time_frame>Predose through 5 months after study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Versus Time Curve (AUC) of Plasma Calcitonin Gene Related Peptide (CGRP)</measure>
    <time_frame>Predose through 5 months after study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of Plasma CGRP</measure>
    <time_frame>Predose through 5 months after study drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">178</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY2951742 Solution Formulation-Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2951742 solution formulation in a prefilled syringe given SC once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Part A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in a prefilled syringe given SC once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2951742 Lyophilized Formulation-Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2951742 lyophilized (freeze dried) formulation given SC once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2951742 Solution Formulation-Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2951742 solution formulation in a prefilled syringe given SC once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2951742</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY2951742 Solution Formulation-Part A</arm_group_label>
    <arm_group_label>LY2951742 Lyophilized Formulation-Part B</arm_group_label>
    <arm_group_label>LY2951742 Solution Formulation-Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo-Part A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female healthy participants

          -  Have a body mass index of 19.0 to 35.0 kilograms per meter square (kg/mÂ²), inclusive

        Exclusion Criteria:

        - Currently smoke in excess of 5 cigarettes/day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2015</study_first_submitted>
  <study_first_submitted_qc>October 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2015</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

